摘要
目的 探讨膀胱尿路上皮癌患者尿中肝细胞生长因子（HGF）和核基质蛋白22（NMP22）表达水平与膀胱尿路上皮癌分期和分级的关系。方法膀胱移行细胞癌（TCC）接受保留膀胱手术的患者48例，均采用吡柔比星（THP）膀胱灌注。采用酶联免疫吸附法（ELISA）分别检测灌注前、灌注后6个月尿中HGF和NMP22的含量。结果术后12个月复发率为12．5％（6／48）。灌注前尿HGF水平随肿瘤的分级、分期升高而增加，各级或期间HGF水平差异均有统计学意义（P〈0．05），NMP22含量随肿瘤分期升高而增加，各期间差异均有统计学意义（均P〈O．05）。HGF、NMP22和尿细胞学检测对膀胱尿路上皮癌术后复发的敏感度分别为100％（6／6）、83.3％（5／6）和66．7％（4／6）；特异度分别为61．9％（26／42）、57．1％（24／42）和97．6％（41／42）。结论HGF和NMP22均为膀胱尿路上皮癌患者尿中良好肿瘤标志物，与肿瘤的分期和分级密切相关，结合尿细胞学检测可以作为膀胱尿路上皮癌早期筛查和诊断的有效指标。
Objective To evaluate the relationship of the hepatocyte growth factor （HGF） and the nuclear matrix protein 22 （NMP22） in urine and the stage and grade of bladder uroepithelium carcinoma. Methods A total of 48 post-operative patients （males 39, females 9） with bladder cancer enrolled in this study were perfused with THP. The voided urine of all the patients before and 6 months after perfusion were recovered selectively. HGF and NMP22 ELISA kits were used to detect bladder cancer. Results The recurrence rate was 12.5 %. The HGF level had positive correlation with the stage and grade of bladder uroepithelium carcinoma （P 〈0.05）. The NMP22 level had positive correlation with the grade of bladder cancer.The sensitivity and specificity of HGF, NMP22 and cytology were 100 % （6/6）, 83.3 % （5/6）, 66.7 % （4/6） and 61.9 % （26/42）, 57.1% （24/42）, 97.6 % （41/42）, respectively. Conclusion The HGF and NMP22 are both valuable tumor markers in the urine of bladder uroepitbelium carcinoma. They have intimate relation with the stage and grade of bladder uroepithelium carcinoma. Hence combined with cytology, they could be selected as the significance level of early screening and diagnosing.
出处
《肿瘤研究与临床》
CAS
2011年第3期179-181,共3页
Cancer Research and Clinic
基金
天津市卫生局科技资助研究项目（04KY20）
关键词
膀胱肿瘤
肝细胞生长因子
核基质相关蛋白质类
Urinary bladder neoplasms
Hepatocyte growth factor
Nuclear matrix-associated proteins
